Cargando…

The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors

The ineffectiveness and failing of chemotherapeutic treatments are often associated with multidrug resistance (MDR). MDR is primarily linked to the overexpression of ATP-binding cassette (ABC) transporter proteins in cancer cells. ABCG2 (ATP-binding cassette subfamily G member 2, also known as the b...

Descripción completa

Detalles Bibliográficos
Autores principales: Stockmann, Philipp, Kuhnert, Lydia, Leinung, Wencke, Lakoma, Cathleen, Scholz, Birte, Paskas, Svetlana, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Honscha, Walther, Hey-Hawkins, Evamarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866861/
https://www.ncbi.nlm.nih.gov/pubmed/36678870
http://dx.doi.org/10.3390/pharmaceutics15010241
_version_ 1784876197003395072
author Stockmann, Philipp
Kuhnert, Lydia
Leinung, Wencke
Lakoma, Cathleen
Scholz, Birte
Paskas, Svetlana
Mijatović, Sanja
Maksimović-Ivanić, Danijela
Honscha, Walther
Hey-Hawkins, Evamarie
author_facet Stockmann, Philipp
Kuhnert, Lydia
Leinung, Wencke
Lakoma, Cathleen
Scholz, Birte
Paskas, Svetlana
Mijatović, Sanja
Maksimović-Ivanić, Danijela
Honscha, Walther
Hey-Hawkins, Evamarie
author_sort Stockmann, Philipp
collection PubMed
description The ineffectiveness and failing of chemotherapeutic treatments are often associated with multidrug resistance (MDR). MDR is primarily linked to the overexpression of ATP-binding cassette (ABC) transporter proteins in cancer cells. ABCG2 (ATP-binding cassette subfamily G member 2, also known as the breast cancer resistance protein (BCRP)) mediates MDR by an increased drug efflux from the cancer cells. Therefore, the inhibition of ABCG2 activity during chemotherapy ought to improve the efficacy of the administered anti-cancer agents by reversing MDR or by enhancing the agents’ pharmacokinetic properties. Significant efforts have been made to develop novel, powerful, selective, and non-toxic inhibitors of BCRP. However, thus far the clinical relevance of BCRP-selective MDR-reversal has been unsuccessful, due to either adverse drug reactions or significant toxicities in vivo. We here report a facile access towards carboranyl quinazoline-based inhibitors of ABCG2. We determined the influence of different methoxy-substitution patterns on the 2-phenylquinazoline scaffold in combination with the beneficial properties of an incorporated inorganic carborane moiety. A series of eight compounds was synthesized and their inhibitory effect on the ABCG2-mediated Hoechst transport was evaluated. Molecular docking studies were performed to better understand the structure-protein interactions of the novel inhibitors, exhibiting putative binding modes within the inner binding site. Further, the most potent, non-toxic compounds were investigated for their potential to reverse ABCG2-mediated mitoxantrone (MXN) resistance. Of these five evaluated compounds, N-(closo-1,7-dicarbadodecaboran(12)-9-yl)-6,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-quinazolin-4-amine (DMQCd) exhibited the strongest inhibitory effect towards ABCG2 in the lower nanomolar ranges. Additionally, DMQCd was able to reverse BCRP-mediated MDR, making it a promising candidate for further research on hybrid inorganic-organic compounds.
format Online
Article
Text
id pubmed-9866861
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98668612023-01-22 The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors Stockmann, Philipp Kuhnert, Lydia Leinung, Wencke Lakoma, Cathleen Scholz, Birte Paskas, Svetlana Mijatović, Sanja Maksimović-Ivanić, Danijela Honscha, Walther Hey-Hawkins, Evamarie Pharmaceutics Article The ineffectiveness and failing of chemotherapeutic treatments are often associated with multidrug resistance (MDR). MDR is primarily linked to the overexpression of ATP-binding cassette (ABC) transporter proteins in cancer cells. ABCG2 (ATP-binding cassette subfamily G member 2, also known as the breast cancer resistance protein (BCRP)) mediates MDR by an increased drug efflux from the cancer cells. Therefore, the inhibition of ABCG2 activity during chemotherapy ought to improve the efficacy of the administered anti-cancer agents by reversing MDR or by enhancing the agents’ pharmacokinetic properties. Significant efforts have been made to develop novel, powerful, selective, and non-toxic inhibitors of BCRP. However, thus far the clinical relevance of BCRP-selective MDR-reversal has been unsuccessful, due to either adverse drug reactions or significant toxicities in vivo. We here report a facile access towards carboranyl quinazoline-based inhibitors of ABCG2. We determined the influence of different methoxy-substitution patterns on the 2-phenylquinazoline scaffold in combination with the beneficial properties of an incorporated inorganic carborane moiety. A series of eight compounds was synthesized and their inhibitory effect on the ABCG2-mediated Hoechst transport was evaluated. Molecular docking studies were performed to better understand the structure-protein interactions of the novel inhibitors, exhibiting putative binding modes within the inner binding site. Further, the most potent, non-toxic compounds were investigated for their potential to reverse ABCG2-mediated mitoxantrone (MXN) resistance. Of these five evaluated compounds, N-(closo-1,7-dicarbadodecaboran(12)-9-yl)-6,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-quinazolin-4-amine (DMQCd) exhibited the strongest inhibitory effect towards ABCG2 in the lower nanomolar ranges. Additionally, DMQCd was able to reverse BCRP-mediated MDR, making it a promising candidate for further research on hybrid inorganic-organic compounds. MDPI 2023-01-10 /pmc/articles/PMC9866861/ /pubmed/36678870 http://dx.doi.org/10.3390/pharmaceutics15010241 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stockmann, Philipp
Kuhnert, Lydia
Leinung, Wencke
Lakoma, Cathleen
Scholz, Birte
Paskas, Svetlana
Mijatović, Sanja
Maksimović-Ivanić, Danijela
Honscha, Walther
Hey-Hawkins, Evamarie
The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors
title The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors
title_full The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors
title_fullStr The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors
title_full_unstemmed The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors
title_short The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors
title_sort more the better—investigation of polymethoxylated n-carboranyl quinazolines as novel hybrid breast cancer resistance protein inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866861/
https://www.ncbi.nlm.nih.gov/pubmed/36678870
http://dx.doi.org/10.3390/pharmaceutics15010241
work_keys_str_mv AT stockmannphilipp themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT kuhnertlydia themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT leinungwencke themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT lakomacathleen themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT scholzbirte themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT paskassvetlana themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT mijatovicsanja themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT maksimovicivanicdanijela themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT honschawalther themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT heyhawkinsevamarie themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT stockmannphilipp morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT kuhnertlydia morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT leinungwencke morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT lakomacathleen morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT scholzbirte morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT paskassvetlana morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT mijatovicsanja morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT maksimovicivanicdanijela morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT honschawalther morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors
AT heyhawkinsevamarie morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors